Proteomics International Laboratories (PIQ) Investor presentation summary

Commercial strategy

• Repositioned for commercial execution, with three lead tests advancing through validation, market access and reimbursement pathways under disciplined capital allocation.

• A distributor-led model combines partner access to clinicians and collection networks with in-house laboratory testing, reporting and quality control.

• Priorities include phased launches, reimbursement evidence, scalable laboratory operations and stronger commercial capabilities.

Lead tests and clinical performance

• Promarker D predicts risk of diabetes-related chronic kidney disease up to 4 years before symptoms; sensitivity 76% and specificity 92%.

• Promarker Eso is a blood-test triage for chronic reflux patients; sensitivity 91% and specificity 98%, with the aim of reducing invasive surveillance endoscopies.

• Promarker Endo supports evaluation of suspected endometriosis; sensitivity ranges from 68% for stages I–IV to 90% for stage IV, with 71% specificity across groups.

• OxiDx measures oxidative stress for specialised diagnostic applications; performance is assessed by indication, with patents granted across key markets.

Market opportunity and commercial access

• Estimated medium-term annual SOM: Promarker D ~20,000 tests in Australia and ~390,000 in the US; Promarker Eso ~15,000 and ~240,000; Promarker Endo ~50,000 and ~360,000.

• Healius is the exclusive Australian pathology distributor for the Promarker portfolio, with a network of ~1,900 collection centres.

• Promarker D and Promarker Eso entered controlled market release in WA and NT on 14 Sep 2026; national rollout is planned for FY27 Q2.

• Initial Australian private-pay prices are A$495 for Promarker D and A$997 for Promarker Eso; Promarker Endo availability is planned for FY27 Q3, with pricing to be confirmed.